Analysis Tools
mortality/aging
|
• median survival is 430 days
|
hematopoietic system
|
• impaired ability to engraft in a competitive repopulation assay
|
|
• severe block in B cell development with few cells progressing past the early pro-B cell stage
|
|
• normal architecture is largely replaced by myeloid progenitors in mice at 3 and 12 months of age
|
|
• decrease in the fraction of functional c-Kit+ Sca-1+ Lin-(KSL)-signaling lymphocyte activation molecule (KSL-SLAM) cells
|
|
• increase in the fractions of c-Kit+ Sca-1+ Lin- (KSL) and multipotent progenitor (Lin-c-Kit+Sca-1+CD135+CD34+) cells in the bone marrow
|
|
• architecture disruption and cellular expansion at 3 and 12 months of age
|
|
• detected at 12 weeks of age
|
|
• treatment with either Lestaurtinib or Sorafenib decreases bone marrow cell proliferation
|
skeleton
|
• architecture disruption and cellular expansion at 3 and 12 months of age
• normal architecture is largely replaced by myeloid progenitors in mice at 3 and 12 months of age
|
immune system
|
• severe block in B cell development with few cells progressing past the early pro-B cell stage
|
|
• architecture disruption and cellular expansion at 3 and 12 months of age
|
|
• detected at 12 weeks of age
|
growth/size/body
|
• detected at 12 weeks of age
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| acute myeloid leukemia | DOID:9119 |
OMIM:601626 |
J:205200 | |
